<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03131544</url>
  </required_header>
  <id_info>
    <org_study_id>Prostate Laser Center BPH 01</org_study_id>
    <nct_id>NCT03131544</nct_id>
  </id_info>
  <brief_title>MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)</brief_title>
  <official_title>MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prostate Laser Center, PLLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic, Inc., a Minnesota, U.S.A. company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Prostate Laser Center, PLLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over 100,000 BPH procedures are performed annually in the US. The purpose of this study is to
      evaluate the effectiveness of performing MRI guided transrectal laser ablation using a 980 nm
      laser (VisualaseTM by Medtronic, Inc., a Minnesota, U.S.A. company) to treat benign prostatic
      hypertrophy (BPH). The laser system will be used to necrotize urological soft tissue within
      the prostate under MRI guidance. This will be a single center, single arm prospective trial
      with an anticipated enrollment of 10 men. Patients who elect this treatment option and choose
      to be part of the study will be enrolled consecutively.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">April 17, 2017</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Prostate Symptom Score (IPSS) Change</measure>
    <time_frame>Time Frame: Baseline, 2 months, 4 months, 6 months and 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>International Prostate Symptom Score Quality of Life Question Change</measure>
    <time_frame>Time Frame: Baseline, 2 months, 4 months, 6 months and 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>BPH Impact Index Change</measure>
    <time_frame>Time Frame: Baseline, 2 months, 4 months, 6 months and 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sexual Health Inventory of Men (SHIM) Score Change</measure>
    <time_frame>Time Frame: Baseline, 2 months, 4 months, 6 months and 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>Continuous until completion of the study at 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>BPH</condition>
  <condition>Prostate Hyperplasia</condition>
  <condition>Urinary Frequency/Urgency</condition>
  <arm_group>
    <arm_group_label>FLA for BPH Active Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI Guided Transrectal Periuretheral Transitional Zone Ablation</intervention_name>
    <description>Patients will undergo an MRI guided transrectal ablation of tissue within the periuretheral transitional zone.</description>
    <arm_group_label>FLA for BPH Active Treatment</arm_group_label>
    <other_name>Visualase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of lower urinary track symptoms (LUTS).

          2. Prostate volume of 40 - 200 cc.

          3. Men ≥ 45 years old.

          4. IPSS ≥ 15.

          5. BPH Impact Index ≥ 5.

        Exclusion Criteria:

          1. History of prostate or bladder cancer, pelvic radiation, untreated bladder stones, or
             findings suggestive of likely underlying prostate cancer.

          2. Need to catheterize to relieve obstruction.

          3. Daily use of incontinence materials/padding.

          4. Neurogenic or hypotonic bladder, Parkinson's Disease, or a history of uncontrolled
             diabetes.

          5. Prior interventional or surgical treatment of BPH.

          6. Penile prosthesis.

          7. Artificial urinary sphincter or collagen bladder injection.

          8. Urethral stricture.

          9. Bleeding disorder/coagulopathy.

         10. Inability to refrain from blood thinners in the peri-procedural period.

         11. Inability or chooses not to provide informed consent.

         12. Any serious medical condition which would make proceeding to treatment unsafe.

         13. Significant contraindication to MRI or gadolinium contrast.

         14. Hip replacement.

         15. Lack of a rectum.

         16. Life expectancy of less than two years.

         17. Unable or unwilling to complete all required questionnaires and follow-up assessments.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Prostate Laser Center, PLLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ProstateLaserCenter.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 16, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>June 27, 2018</last_update_submitted>
  <last_update_submitted_qc>June 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BPH</keyword>
  <keyword>Benign Prostatic Hypertrophy</keyword>
  <keyword>MRI</keyword>
  <keyword>Prostate</keyword>
  <keyword>Lower Urinary Tract Symptoms</keyword>
  <keyword>Nocturia</keyword>
  <keyword>Incomplete bladder emptying</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

